Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in newly diagnosed glioblastoma multiforme
NCT03047473Phase 2Completed
- Sponsor
- Clinique Neuro-Outaouais
- Start
- May 2017
- Primary completion
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in glioblastoma multiforme (GBM), sponsored by Clinique Neuro-Outaouais. Started May 2017; status: completed.
02
Drugs
avelumab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT03047473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03047473.